Quantcast

Aeterna Zentaris Announces Poster Presentation on Final Phase 2 Results for AEZS-108 in Endometrial Cancer at Upcoming European Society of Gynaecological Oncology Meeting

July 18, 2011

QUÓ°BEC CITY, July 18, 2011 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the “Company”)  today announced that final Phase 2
results in endometrial cancer on its anticancer compound, AEZS-108,
will be presented during a poster session at the upcoming 17(th) International Meeting of the European Society of Gynaecological
Oncology (“ESGO”), to be held September 11-14, 2011, at the Milan
Convention Center in Milan, Italy. The trial was conducted by the
German AGO Study Group and study centers in Bulgaria. AEZS-108, a
targeted cytotoxic peptide conjugate, is currently in Phase 1/2
programs in prostate and bladder cancer, and has successfully completed
Phase 2 trials in endometrial and ovarian cancer.


    Abstract #247:   "AGO-GYN 5 - (Phase II) study with AEZS-108, a
                     targeted cytotoxic LHRH analog in patients with LHRH
                     receptor positive endometrial cancer", Wimberger P.,
                     Gorchev G., Hanker L., Stähle A., Hristamian A.,
                     Beckmann M.W., Dall P., Grndker C., Hilpert F.,
                     Sehouli J., Harter P., Taskova V., Emons G., AGO Study
                     Group, Germany

    Presenter:       Pauline Wimberger, MD, Gynaecology and Obstetrics,
                     University of Duisburg-Essen, Essen, Germany

    Poster Session:  Poster Shift III

    Date and time:   September 14, 2011 / 7:00-8:00 am (local time)

    Venue:           Milan Convention Center, Milan, Italy

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a hybrid
molecule composed of a synthetic peptide carrier and a well-known
chemotherapy agent, doxorubicin. Phase 2 studies for the treatment of
endometrial and ovarian cancer have been successfully completed, and
Phase 1/2 trials are being conducted in prostate and bladder cancer.
AEZS-108 is the first intravenous drug in a clinical study that directs
the chemotherapy agent specifically to

LHRH-receptor expressing tumors, resulting in more targeted treatment
with less damage to healthy tissue. AEZS-108 has been granted
orphan-drug designation by the FDA and orphan medicinal product
designation from the EMA for the treatment of ovarian cancer. Aeterna
Zentaris owns the worldwide rights to AEZS-108.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company
currently investigating potential treatments for various cancers
including colorectal, multiple myeloma, endometrial, ovarian, prostate
and bladder cancer. The Company’s innovative approach of “personalized
medicine” means tailoring treatments to a patient’s specific condition
and to unmet medical needs. Aeterna Zentaris’ deep pipeline is drawn
from its proprietary discovery unit providing the Company with constant
and long-term access to state-of-the-art therapeutic options. For more
information please visit www.aezsinc.com

 

SOURCE AETERNA ZENTARIS INC.


Source: newswire



comments powered by Disqus